Santen Seiyaku KK
4536
ISIN JP3336000009 / Valor 763395
Santen Seiyaku KK
UMushroom community rating:
About company
Santen Seiyaku KK is a global pharmaceutical company specializing in the research, development, manufacturing, and marketing of eye care products. The company focuses on providing innovative solutions to support eye health, serving approximately 50 million people worldwide. Santen's product portfolio includes treatments for a range of ocular conditions, such as glaucoma, dry eye, and retinal disorders. With a strong emphasis on scientific research and development, Santen aims to address unmet medical needs in ophthalmology and improve the quality of life for patients with eye-related health issues.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Revenue Growth
Santen Seiyaku KK reported a revenue increase of 3.3% year-on-year for the three months ended June 30, 2024, reaching ¥74.8 billion. This growth was driven by the expansion of sales of new and mainstay products, despite challenges such as NHI price revisions and a voluntary recall of Diquas LX in Japan.
Core Operating Profit
For the same period, Santen Seiyaku KK's core operating profit rose by 2.2% year-on-year to ¥15.9 billion. The increase in core operating profit reflects the company's effective cost management and strategic focus on high-performing products across various markets.
Net Profit
Santen Seiyaku KK's net profit for the three months ended June 30, 2024, was ¥10.6 billion, showing a slight increase from ¥10.4 billion in the same period of the previous year. This modest growth in net profit indicates stable financial performance amidst market challenges.
Dividends
The company announced a forecasted annual dividend of ¥34.00 per share for the fiscal year ending March 31, 2025, up from ¥33.00 per share in the previous fiscal year. This increase in dividends reflects Santen Seiyaku KK's commitment to returning value to its shareholders.
Financial Position
As of June 30, 2024, Santen Seiyaku KK's total assets stood at ¥434.2 billion, with total equity attributable to owners of the company at ¥306.7 billion. The equity ratio improved to 70.6%, indicating a strong financial position and enhanced shareholder value.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
4569 M
Market cap (USD)
878,100
Daily traded volume (Shares)
1788.5 / 1762
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
